September 25, 2022

by Joe Hope

– Advertisement –

– Advertisement –

Shares of Faron Pharmaceuticals Oyj rose on Tuesday after it said top-line data from its phase 1/2 trial returned positive results for its bexmarilimab cancer treatment.

Shares were up 0.18 pence, or 8.4%, at 2.38 pence at 0826 GMT.

– Advertisement –

The Finnish pharmaceutical company said the new data, along with recent scientific advisory board recommendations and pharmacokinetic modeling, will allow it to file the end of a Phase 1/2 package with the US Food and Drug Administration in late 2022.

The latest advances with trials focused on higher dose levels and frequencies to finalize doses for future study designs.

The company said that bexamarilimab was well tolerated in patients receiving higher dosage levels or more frequent administration, and induced significant systemic interferon gamma enhancement — the ability of the treatment to activate an immune response in cancer patients. It reflects.

The median survival rate for patients in Parts 1 and 2 of the trial was 14.9 months, compared with 4.4 months for those not treated with bexamilimumab.

Chief Executive Markku Jalkanan said, “We now have a clearer understanding of which patients benefit from bexamarilimab treatment and can identify them using a validated staining antibody, which is widely accessible and routine practice.” can be adapted for.”

Write to Joe Hope at [email protected]

See also  To become a data scientist and engineer! , r-bloggers